Peripherally inserted central catheters in allogeneic hematopoietic stem cell transplant recipients.


Journal

Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
ISSN: 1433-7339
Titre abrégé: Support Care Cancer
Pays: Germany
ID NLM: 9302957

Informations de publication

Date de publication:
Sep 2020
Historique:
received: 15 06 2019
accepted: 23 12 2019
pubmed: 5 1 2020
medline: 25 9 2020
entrez: 5 1 2020
Statut: ppublish

Résumé

Central venous catheters (CVC) are essential for the management of patients with hematologic malignancies, facilitating chemotherapy infusion, antibiotics, parenteral nutrition, blood products, and blood samples collection. In this population, peripherally inserted central catheters (PICC) seem to be associated with lower complications, compared with conventional percutaneously inserted devices (CICC). Data on the PICC in allogeneic hematopoietic stem cell recipients (allo-HSCT) are limited. We have prospectively evaluated the safety and efficacy of 100 polyurethanes or silicone PICC, inserted into 100 adult allo-HSCT recipients, at the Hematology of Sapienza University of Rome (Italy), between October 2012 and August 2017. The median duration of PICC placement was 117 days. Overall, 68% of patients maintained the device for the entire transplant procedure and PICC were removed after day 100 from allo-HSCT; of these, 44% did not experienced any PICC-related complications. Catheter-related bloodstream infections (CRBSI) occurred in 32% of patients (2.5/1000 PICC days), associated with thrombosis in 8 cases. CRBSI were observed in 42% of patients with polyurethane and 20% with silicone PICC (p = 0.02). Catheter-related thrombosis occurred in 9% of patients, never requiring anticipated PICC removal. Mechanical complications occurred in 15% of cases (1.2/1000 PICC days). On the whole, adverse events were manageable and did not affect transplant outcome. No deaths related to PICC-complications were observed. PICC are a safe and reliable long-term venous access in allo-HSCT recipients.

Sections du résumé

BACKGROUND BACKGROUND
Central venous catheters (CVC) are essential for the management of patients with hematologic malignancies, facilitating chemotherapy infusion, antibiotics, parenteral nutrition, blood products, and blood samples collection. In this population, peripherally inserted central catheters (PICC) seem to be associated with lower complications, compared with conventional percutaneously inserted devices (CICC). Data on the PICC in allogeneic hematopoietic stem cell recipients (allo-HSCT) are limited.
METHODS METHODS
We have prospectively evaluated the safety and efficacy of 100 polyurethanes or silicone PICC, inserted into 100 adult allo-HSCT recipients, at the Hematology of Sapienza University of Rome (Italy), between October 2012 and August 2017.
RESULTS RESULTS
The median duration of PICC placement was 117 days. Overall, 68% of patients maintained the device for the entire transplant procedure and PICC were removed after day 100 from allo-HSCT; of these, 44% did not experienced any PICC-related complications. Catheter-related bloodstream infections (CRBSI) occurred in 32% of patients (2.5/1000 PICC days), associated with thrombosis in 8 cases. CRBSI were observed in 42% of patients with polyurethane and 20% with silicone PICC (p = 0.02). Catheter-related thrombosis occurred in 9% of patients, never requiring anticipated PICC removal. Mechanical complications occurred in 15% of cases (1.2/1000 PICC days). On the whole, adverse events were manageable and did not affect transplant outcome. No deaths related to PICC-complications were observed.
CONCLUSIONS CONCLUSIONS
PICC are a safe and reliable long-term venous access in allo-HSCT recipients.

Identifiants

pubmed: 31900609
doi: 10.1007/s00520-019-05269-z
pii: 10.1007/s00520-019-05269-z
doi:

Substances chimiques

Polyurethanes 0
Silicones 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

4193-4199

Auteurs

Elena Mariggiò (E)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy. mariggio@bce.uniroma1.it.

Anna Paola Iori (AP)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Alessandra Micozzi (A)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Antonio Chistolini (A)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Roberto Latagliata (R)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Paola Berneschi (P)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Massimo Giampaoletti (M)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Ursula La Rocca (U)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Antonella Bruzzese (A)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Walter Barberi (W)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Robin Foà (R)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Salvatore Giacomo Morano (SG)

Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Rome, Via Benevento 6, 00161, Roma, RM, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH